In a small human trial in SMA patients neurostimulation sessions improved motoneuron function, reduced fatigue, and improved leg muscle strength and walking.

ABSTRACT: One serious lesion to the central nervous system is spinal cord injury (SCI). Due to its intricate pathophysiological mechanisms and the irreparability of nerve cells, conventional ...

While Venn diagrams may not have solved any long-standing open problems, surely these interlocking rings deserve more credit. Their compact representation of group relationships explains their ...

Spinal muscular atrophy (SMA) is a progressive genetic neuromuscular condition affecting spinal motor neurons. The underlying cause of SMA is deletions or mutations in the SMN gene. It is classified ...

Muscle atrophy is a primary characteristic ... Limitations: Different diseases have complex and diverse pathogenic mechanisms, making it difficult to find a single model that represents all ...

Seeking urgent Union government intervention to overcome the lack of affordable access to medicines for treating Spinal Muscular Atrophy (SMA ... classified as a rare disease and there are ...

who are living with Spinal Muscular Atrophy (SMA) with the support of her mother, sister and teacher. Ms. Keya was felicitated by the Visakha Rasagna Vedika, a cultural organisation, at the Public ...

Treatment with OAV101 IT, a formulation of the gene therapy Zolgensma (onasemnogene abeparvovec-xioi) that’s delivered directly into the spinal canal, safely led to motor improvements for children ...

Back to Healio Topline results from a phase 3 clinical trial showed an investigational gene therapy for young people with spinal muscular atrophy type 2 increased mobility and slowed disease ...

Their findings suggest that tau’s transformation may actually begin as a defensive mechanism against viral infection rather than simply being a destructive force. Brain tissue samples from individuals ...

Burghes AHM, Beattie CE. Spinal muscular atrophy: why do low levels of SMN make motor neurons sick? Nat Rev Neurosci. 2009;10(8):597-609. doi:10.1038/nrn2670 20. Tisdale S, Pellizzoni L. Disease ...